Company news

GeneDx Holdings Corp. news in 2023

GeneDx Holdings Corp.'s news releases, calls and decks from 2023, newest first.

View company

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy

November 30, 2023

GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference

November 27, 2023

GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights

October 29, 2023

GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023

October 8, 2023

GeneDx Announces Evolution of Executive Leadership Team

September 10, 2023

GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced

September 5, 2023

GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine

August 20, 2023

GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights

August 7, 2023

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

August 6, 2023

GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options

July 18, 2023

GeneDx to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

July 17, 2023

GeneDx to Present New Data on Urine Mitochondrial DNA Testing at the 2023 United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium

June 27, 2023

GeneDx Announces New Tool to Help Harness Human Pangenome Diversity for Clinical Interpretation of Variants

June 25, 2023

GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients

June 19, 2023

GeneDx to Participate in Upcoming Investor Conferences in June

May 23, 2023

GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations

May 22, 2023

GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 21, 2023

GeneDx Reports First Quarter 2023 Financial Results and Business Highlights

May 8, 2023

GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option

May 3, 2023

GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders

May 2, 2023

GeneDx Announces Reverse Stock Split

April 27, 2023

GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023

April 17, 2023

GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel

April 2, 2023

GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

March 19, 2023

GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray

March 15, 2023

GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

March 13, 2023

GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference

February 28, 2023

GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting

February 27, 2023

GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023

February 20, 2023

GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases

February 15, 2023

GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering

January 30, 2023

GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery

January 29, 2023

GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering

January 26, 2023

GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering

January 25, 2023

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

January 8, 2023

Calls in 2023

Decks in 2023